Abstract
Automation has long been a resource for high-throughput screening at Bristol-Myers Squibb. However, with growing deck sizes and decreasing time lines, a new generation of more robust, supportable automated systems was necessary for accomplishing high-throughput screening goals. Implementation of this new generation of automated systems required numerous decisions concerning hardware, software and the value of in-house automation expertise. This project has resulted in fast, flexible, industrialized automation systems with a strong in-house support structure that we believe meets our current high-throughput screening requirements and will continue to meet them well into the future.
Full Text
The Full Text of this article is available as a PDF (133.2 KB).